Application

AZD1152-HQPA has been used as a specific inhibitor of aurora kinase B (AURKB) to examine the cell cycle stage the IRG (hit compound that induces an irregular nuclear shape)-treated cells accumulate and become senescent and also to study the roles of cyclin-dependent kinase 6 (CDK6) and AURKB in restricting enterovirus 71 (EV71) infection.

AZD1152-HQPA has been used:for the dose dependent inhibition of aurora kinase B (AURKB)as a component to identify that, replication timing regulatory factor 1 (RIF1) and protein phosphatase 1 (PP1) are critical for the regulation of abscission timing in human cellsas a component to study the relevance of AURKB as a cancer therapeutic target

Biochem/physiol Actions

AZD1152-HQPA is the active metabolite of AZD-1152, a potent selective Aurora Kinase B inhibitor. AZD1152 is 50-fold selective for Aurora kinase B over Aurora kinase C and over 1000-fold selective for Aurora kinase B over Aurora Kinase A. (IC50s: aurora-A, 1,369 nmol/L; aurora-B, 0.36 nmol/L; aurora-C, 17.0 nmol/L). It is converted in plasma to the active form AZD1152-HQPA, which has been shown to have antineoplastic activity in a variety of animal models and human cancer cell lines.

Other Notes

AZD1152-HQPA has been expertly reviewed and recommended by the Chemical Probes Portal. For more information, please visit the AZD1152-HPQA probe summary on the Chemical Probes Portal website.

Packaging

10, 50 mg in glass bottle